Publications by authors named "Oscar Alfredo Castillo Trujillo"
Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913).
Nat Commun
August 2024
Article Synopsis
- Patients with advanced high-grade digestive neuroendocrine neoplasms (NENs) have a poor prognosis, but adding immune checkpoint inhibition to chemotherapy may improve their survival rates.
- The NICE-NEC trial tested nivolumab alongside carboplatin and etoposide in chemotherapy-naive patients and measured various outcomes, including overall survival and response rates.
- While the primary survival rate goal was not met, the treatment was linked to a median overall survival of 13.9 months and 37.6% of patients surviving more than 2 years, with manageable safety concerns.
Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study.
Clin Transl Oncol
October 2024
Purpose: RAS (KRAS/NRAS) mutational status on a tumor biopsy is mandatory to guide the best treatment in metastatic colorectal cancer (mCRC). Determining the RAS mutational status by tumor-tissue biopsy is essential in guiding the optimal treatment decision for mCRC. RAS mutations are negative predictive factors for the use of EGFR monoclonal antibodies.
View Article and Find Full Text PDFImpact of systemic cancer treatment on quality of life and mental well-being: a comparative analysis of patients with localized and advanced cancer.
Clin Transl Oncol
December 2023
Introduction: This study investigated the impact of systemic cancer therapy on the quality of life, mental well-being, and life satisfaction of cancer patients.
Methods: This prospective study was promoted by the Spanish Society of Medical Oncology (SEOM) and enrolled patients with localized, resected, or unresectable advanced cancer from 15 Spanish medical oncology departments. Patients completed surveys on quality of life (EORTC-QoL-QLQ-C30), psychological distress (BSI-18) and life satisfaction (SWLS) before and after systemic cancer treatment.
Evolution of Mutations in Cell-Free DNA of Patients with Tissue Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study.
Cancers (Basel)
December 2022
The serial analysis of cell-free DNA (cfDNA) enables minimally invasive monitoring of tumor evolution, providing continuous genetic information. PERSEIDA was an observational, prospective study assessing the cfDNA (/) mutational status evolution in first-line, metastatic CRC, wild-type (according to baseline tumor tissue biopsy) patients. Plasma samples were collected before first-line treatment, after 20 ± 2 weeks, and at disease progression.
View Article and Find Full Text PDFObjective: Cancer patients are at increased risk for psychological difficulties and COVID-19. We sought to analyze anxiety and depression levels during the COVID-19 pandemic and the association between sociodemographic, clinical, and psychological factors in patients with advanced cancer.
Methods: A prospective, multicenter cohort of 401 consecutive patients with newly diagnosed, advanced cancer completed the Brief Symptom Inventory, Michel Uncertainty in Illness Scale, Herth Hope Index, and Cancer Worry Scale between February 2020 and May 2021.